Uncategorized

Chinese leading biopharmaceutical company 3SBio announced its 2022 annual results.

Mesoblast Limited announced that, as part of the ongoing review of the BLA for remestemcel-L in the treatment of children with SR-aGVHD, the United States Food and Drug Administration has scheduled a Pre-License Inspection of Mesoblast’s cell therapy manufacturing operations at Lonza Bioscience in Singapore.

Sequana Medical NV announces further strengthening of the intellectual property portfolio for its DSR program.

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA®.

POXEL SA announced that it will report its 2022 full year results by the end of March 2023.

The companies are working together to allow physicians and developers to build AI applications for Medtronic devices, beginning with the GI Genius endoscopy platform.

Una nueva investigación demuestra la importancia de analizar los efectos de estresores ambientales en conjunto.   Estresores ambientales fruto de la acción humana como el calentamiento global, la acidificación de los suelos o la contaminación crean sinergias que em …

With some proactive measures, you can make it more likely your stocks will remain yours in the event of a layoff. 

DAX Express will be Nuance’s first fully automated clinical documentation software. Historically, Nuance has sent the notes generated by its AI to a human for quality review before returning them to physicians.

Following recent meetings with the FDA and European Medicines Agency, Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.